Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in patients with childhood systemic lupus erythematosus: a real-world interventional multi-centre study.
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Rotstein Grein, Ingrid HertaPinto, Natalia Ferreira
Lobo, Aline
Groot, Noortje
Sztajnbok, Flavio
da Silva, Clóvis Artur Almeida
Paim Marques, Luciana B
Appenzeller, Simone
Islabão, Aline Garcia
Magalhães, Claudia Saad
de Almeida, Rozana Gasparello
Bica, Blanca
Fraga, Melissa
da Fraga, Aline Coelho Moreira
Dos Santos, Maria Carolina
Robazzi, Teresa
Terreri, Maria Teresa Ra
Bandeira, Marcia
Pasmans, Hella
Schepp, Rutger
van der Klis, Fiona
de Roock, Sytze
Wulffraat, Nico
Pileggi, Gecilmara
Type
ArticleLanguage
en
Metadata
Show full item recordTitle
Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in patients with childhood systemic lupus erythematosus: a real-world interventional multi-centre study.Published in
Lupus 2020; 29(8):934-42PMID
32501172ae974a485f413a2113503eed53cd6c53
10.1177/0961203320928406
Scopus Count
Collections
Related articles
- Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in patients with juvenile dermatomyositis: a real-world multicentre study.
- Authors: Grein IHR, Pinto NBF, Groot N, Martins CB, Lobo A, Aikawa NE, Barbosa C, Terreri MT, da Fraga ACM, de Oliveira SKF, Sztajnbok F, Paim Marques LB, Islabão AG, Appenzeller S, Bica B, de Oliveira Sato J, Magalhães CS, Ferriani V, Pasmans H, Schepp R, van der Klis F, de Roock S, Wulffraat N, Pileggi GS
- Issue date: 2020 Nov 11
- Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial.
- Authors: Huh WK, Joura EA, Giuliano AR, Iversen OE, de Andrade RP, Ault KA, Bartholomew D, Cestero RM, Fedrizzi EN, Hirschberg AL, Mayrand MH, Ruiz-Sternberg AM, Stapleton JT, Wiley DJ, Ferenczy A, Kurman R, Ronnett BM, Stoler MH, Cuzick J, Garland SM, Kjaer SK, Bautista OM, Haupt R, Moeller E, Ritter M, Roberts CC, Shields C, Luxembourg A
- Issue date: 2017 Nov 11
- Evaluation of the immunogenicity of the quadrivalent HPV vaccine using 2 versus 3 doses at month 21: An epidemiological surveillance mechanism for alternate vaccination schemes.
- Authors: Hernández-Ávila M, Torres-Ibarra L, Stanley M, Salmerón J, Cruz-Valdez A, Muñoz N, Herrero R, Villaseñor-Ruíz IF, Lazcano-Ponce E
- Issue date: 2016
- Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa.
- Authors: Mugo N, Ansah NA, Marino D, Saah A, Garner EI
- Issue date: 2015
- The effect of a booster dose of quadrivalent or bivalent HPV vaccine when administered to girls previously vaccinated with two doses of quadrivalent HPV vaccine.
- Authors: Gilca V, Sauvageau C, Boulianne N, De Serres G, Crajden M, Ouakki M, Trevisan A, Dionne M
- Issue date: 2015